{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T19:14:22Z","timestamp":1794338062557,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]},{"name":"Guangdong Esophageal Cancer Research Institute, China","award":["No.M202411"],"award-info":[{"award-number":["No.M202411"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15142-4","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:13:13Z","timestamp":1764583993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Albumin-bound paclitaxel and cisplatin with radiotherapy in locally advanced oesophageal squamous cell carcinoma: a single-arm, phase II trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Shasha","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanjiebubi","family":"Makelike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoqiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanjun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"3","key":"15142_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"15142_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.20892\/j.issn.2095-3941.2016.0093","volume":"14","author":"H Liang","year":"2017","unstructured":"Liang H, Fan J-H, Qiao Y-L. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 2017;14(1):33\u201341. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2016.0093.","journal-title":"Cancer Biol Med"},{"issue":"17","key":"15142_CR3","first-page":"1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u2009\u2013\u200901). Radiation Therapy Oncol Group JAMA. 1999;281(17):1623\u20137.","journal-title":"Radiation Therapy Oncol Group JAMA"},{"issue":"5","key":"15142_CR4","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (radiation therapy oncology group 94\u2009\u2013\u200905) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167\u201374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15142_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0360-3016(96)00591-3","volume":"37","author":"LE Gaspar","year":"1997","unstructured":"Gaspar LE, Qian C, Kocha WI, Coia LR, Herskovic A, Graham M. A phase I\/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92\u2009\u2013\u200907): preliminary toxicity report. Int J Radiat Oncol Biol Phys. 1997;37(3):593\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"15142_CR6","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdp069","volume":"20","author":"S Lorenzen","year":"2009","unstructured":"Lorenzen S, Schuster T, Porschen R, Al-Batran SE, Hofheinz R, Thuss-Patience P, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the arbeitsgemeinschaft internistische onkologie. Ann Oncol. 2009;20(10):1667\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdp069.","journal-title":"Ann Oncol"},{"issue":"3","key":"15142_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0360-3016(92)90888-O","volume":"22","author":"RB Tishler","year":"1992","unstructured":"Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys. 1992;22(3):613\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"14","key":"15142_CR8","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/jnci\/86.14.1086","volume":"86","author":"JA Ajani","year":"1994","unstructured":"Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86(14):1086\u201391.","journal-title":"J Natl Cancer Inst"},{"issue":"2 Suppl 1","key":"15142_CR9","first-page":"12","volume":"9","author":"L Milas","year":"1999","unstructured":"Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol. 1999;9(2 Suppl 1):12\u201326.","journal-title":"Semin Radiat Oncol"},{"issue":"8","key":"15142_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.addr.2007.08.044","volume":"60","author":"MJ Hawkins","year":"2008","unstructured":"Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60(8):876\u201385. https:\/\/doi.org\/10.1016\/j.addr.2007.08.044.","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"15142_CR11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"15142_CR12","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-07-4592","volume":"14","author":"ER Gardner","year":"2008","unstructured":"Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, et al. Randomized crossover pharmacokinetic study of solvent-based Paclitaxel and nab-paclitaxel. Clin Cancer Res. 2008;14(13):4200\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4592.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"15142_CR13","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1200\/JCO.2014.59.5298","volume":"33","author":"HS Rugo","year":"2015","unstructured":"Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, et al. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound Nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502\/NCCTG N063H (Alliance). J Clin Oncol. 2015;33(21):2361\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.59.5298.","journal-title":"J Clin Oncol"},{"key":"15142_CR14","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.2147\/OTT.S108580","volume":"9","author":"H-Y Wang","year":"2016","unstructured":"Wang H-Y, Yao Z-H, Tang H, Zhao Y, Zhang X-S, Yao S-N, et al. Weekly nanoparticle albumin-bound Paclitaxel in combination with cisplatin versus weekly solvent-based Paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Onco Targets Ther. 2016;9:5663\u20139.","journal-title":"Onco Targets Ther"},{"key":"15142_CR15","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.2147\/OTT.S168275","volume":"11","author":"D Wang","year":"2018","unstructured":"Wang D, Zhang W, Qian D, Guan Y, Chen X, Zhang H, et al. Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial. Onco Targets Ther. 2018;11:6333\u20138. https:\/\/doi.org\/10.2147\/OTT.S168275.","journal-title":"Onco Targets Ther"},{"key":"15142_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004291","author":"J Liu","year":"2022","unstructured":"Liu J, Yang Y, Liu Z, Fu X, Cai X, Li H, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004291.","journal-title":"J Immunother Cancer"},{"issue":"14","key":"15142_CR17","doi-asserted-by":"publisher","first-page":"15187","DOI":"10.1002\/cam4.6205","volume":"12","author":"H Jiang","year":"2023","unstructured":"Jiang H, Li Q, Chen B, Xi M, Makelike K, Liu S, et al. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Med. 2023;12(14):15187\u201398. https:\/\/doi.org\/10.1002\/cam4.6205.","journal-title":"Cancer Med"},{"issue":"2","key":"15142_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"15142_CR19","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, MD: U.S. Department of Health and Human Services; 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Cited 27 Oct 2025."},{"issue":"282","key":"15142_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"L KE","year":"1958","unstructured":"KE L, Paul M. Nonparametric Estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381.","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"15142_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24288-1","volume":"12","author":"S Liu","year":"2021","unstructured":"Liu S, Luo L, Zhao L, Zhu Y, Liu H, Li Q, et al. Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial. Nat Commun. 2021;12(1):4014. https:\/\/doi.org\/10.1038\/s41467-021-24288-1.","journal-title":"Nat Commun"},{"issue":"3","key":"15142_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ijrobp.2022.07.007","volume":"114","author":"H Takeuchi","year":"2022","unstructured":"Takeuchi H, Ito Y, Machida R, Kato K, Onozawa M, Minashi K, et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II\/III esophageal squamous cell carcinoma (JCOG0909 study). Int J Radiat Oncol Biol Phys. 2022;114(3):454\u201362. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.007.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"15142_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0120","volume":"5","author":"D Ai","year":"2022","unstructured":"Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, et al. Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer: a randomized clinical trial. JAMA Netw Open. 2022;5(2):e220120. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0120.","journal-title":"JAMA Netw Open"},{"issue":"18","key":"15142_CR24","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.7150\/jca.20053","volume":"8","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Zhang W, Li Q, Li Q, Qiu B, Liu H, et al. A phase II randomized controlled trial: definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with oesophageal squamous cell carcinoma. J Cancer. 2017;8(18):3657\u201366. https:\/\/doi.org\/10.7150\/jca.20053.","journal-title":"J Cancer"},{"issue":"4","key":"15142_CR25","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor Paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound Paclitaxel, ABI-007, compared with cremophor-based Paclitaxel. Clin Cancer Res. 2006;12(4):1317\u201324.","journal-title":"Clin Cancer Res"},{"issue":"20","key":"15142_CR26","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO.18.02122","volume":"37","author":"Y Chen","year":"2019","unstructured":"Chen Y, Ye J, Zhu Z, Zhao W, Zhou J, Wu C, et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase III clinical trial. J Clin Oncol. 2019;37(20):1695\u2013703. https:\/\/doi.org\/10.1200\/JCO.18.02122.","journal-title":"J Clin Oncol"},{"key":"15142_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4137\/CMO.S38204","volume":"10","author":"MA Osman","year":"2016","unstructured":"Osman MA, Elkady MS, Nasr KE. Weekly Paclitaxel versus Three-Weekly Paclitaxel in recurrent Platinum-Resistant epithelial ovarian and peritoneal cancers: A phase III study. Clin Med Insights Oncol. 2016;10:35\u201341. https:\/\/doi.org\/10.4137\/CMO.S38204.","journal-title":"Clin Med Insights Oncol"},{"issue":"5","key":"15142_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/028418602320404998","volume":"41","author":"P Rosenberg","year":"2002","unstructured":"Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al. Randomized trial of single agent Paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41(5):418\u201324.","journal-title":"Acta Oncol"},{"issue":"4","key":"15142_CR29","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.18632\/aging.203919","volume":"14","author":"S Lin","year":"2022","unstructured":"Lin S, Peng T, Meng Y, Cao C, Gao P, Wu P, et al. Comparison of one-week versus three-week Paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis. Aging. 2022;14(4):1959\u201382. https:\/\/doi.org\/10.18632\/aging.203919.","journal-title":"Aging"},{"issue":"3","key":"15142_CR30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.lungcan.2011.12.001","volume":"76","author":"G Gao","year":"2012","unstructured":"Gao G, Chu H, Zhao L, Gui T, Xu Q, Shi J. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer. 2012;76(3):380\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2011.12.001.","journal-title":"Lung Cancer"},{"issue":"4","key":"15142_CR31","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/annonc\/mdx009","volume":"28","author":"J Liang","year":"2017","unstructured":"Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017;28(4):777\u201383. https:\/\/doi.org\/10.1093\/annonc\/mdx009.","journal-title":"Ann Oncol"},{"issue":"8","key":"15142_CR32","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamaoncol.2016.4280","volume":"3","author":"CE Steuer","year":"2017","unstructured":"Steuer CE, Behera M, Ernani V, Higgins KA, Saba NF, Shin DM, et al. Comparison of concurrent use of thoracic radiation with either Carboplatin-Paclitaxel or Cisplatin-Etoposide for patients with stage III non-small-cell lung cancer: a systematic review. JAMA Oncol. 2017;3(8):1120\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4280.","journal-title":"JAMA Oncol"},{"key":"15142_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jconrel.2019.04.013","volume":"303","author":"X Zang","year":"2019","unstructured":"Zang X, Lee JB, Deshpande K, Garbuzenko OB, Minko T, Kagan L. Prevention of paclitaxel-induced neuropathy by formulation approach. J Control Release. 2019;303:109\u201316. https:\/\/doi.org\/10.1016\/j.jconrel.2019.04.013.","journal-title":"J Control Release"},{"issue":"9","key":"15142_CR34","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jtho.2021.03.027","volume":"16","author":"Y Yoneshima","year":"2021","unstructured":"Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, et al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol. 2021;16(9):1523\u201332. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.027.","journal-title":"J Thorac Oncol"},{"issue":"31","key":"15142_CR35","doi-asserted-by":"publisher","first-page":"50624","DOI":"10.18632\/oncotarget.9562","volume":"7","author":"Y Fan","year":"2016","unstructured":"Fan Y, Jiang Y, Zhou X, Chen Q, Huang Z, Xu Y, et al. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget. 2016;7(31):50624\u201334. https:\/\/doi.org\/10.18632\/oncotarget.9562.","journal-title":"Oncotarget"},{"issue":"30","key":"15142_CR36","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.22.02624","volume":"41","author":"N Colombo","year":"2023","unstructured":"Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, et al. Relacorilant\u2009+\u2009Nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, open-label phase II study. J Clin Oncol. 2023;41(30):4779\u201389. https:\/\/doi.org\/10.1200\/JCO.22.02624.","journal-title":"J Clin Oncol"},{"key":"15142_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.04.002","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chen X, Li Y, Qin J, Fang Y, Yang Z, et al. Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma. J Natl Cancer Center. 2022. https:\/\/doi.org\/10.1016\/j.jncc.2022.04.002.","journal-title":"J Natl Cancer Center"},{"issue":"1","key":"15142_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/ONCO.13524","volume":"26","author":"H Hayashi","year":"2021","unstructured":"Hayashi H, Ogura M, Niwa T, Yokoyama T, Tanizaki J, Ozaki T, et al. Phase I\/II study of cisplatin plus nab-paclitaxel with concurrent thoracic radiotherapy for patients with locally advanced non-small cell lung cancer. Oncologist. 2021;26(1):19. https:\/\/doi.org\/10.1002\/ONCO.13524.","journal-title":"Oncologist"},{"key":"15142_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2517-5","volume":"16","author":"Y Huang","year":"2016","unstructured":"Huang Y, Liang W, Yang Y, Zhao L, Zhao H, Wu X, et al. Phase i\/ii dose-finding study of nanoparticle albumin-bound Paclitaxel (nab\u00ae-Paclitaxel) plus cisplatin as treatment for metastatic nasopharyngeal carcinoma. BMC Cancer. 2016;16:464. https:\/\/doi.org\/10.1186\/s12885-016-2517-5.","journal-title":"BMC Cancer"},{"key":"15142_CR40","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2147\/OTT.S44406","volume":"6","author":"Y Shi","year":"2013","unstructured":"Shi Y, Qin R, Wang Z-K, Dai G-H. Nanoparticle albumin-bound Paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther. 2013;6:585\u201391. https:\/\/doi.org\/10.2147\/OTT.S44406.","journal-title":"Onco Targets Ther"},{"issue":"4","key":"15142_CR41","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(23)00060-8","volume":"24","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, et al. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 2023;24(4):371\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(23)00060-8.","journal-title":"Lancet Oncol"},{"key":"15142_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.07.538","author":"Q Pang","year":"2018","unstructured":"Pang Q, Li X, Zhang W, Qian D, Zhang B, Chen X, et al. Safety and effect of radiation therapy combined with anti-PD-1 antibody SHR-1210 as first-line treatment on patients with intolerable concurrent chemoradiotherapy esophageal cancer: a phase 1B clinical trial. Int J Radiat Oncol Biol Phys. 2018. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.538.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"15142_CR43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1971418","author":"W Zhang","year":"2021","unstructured":"Zhang W, Yan C, Zhang T, Chen X, Pang Q. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. Oncoimmunology. 2021. https:\/\/doi.org\/10.1080\/2162402X.2021.1971418.","journal-title":"Oncoimmunology"},{"key":"15142_CR44","doi-asserted-by":"publisher","first-page":"S1124","DOI":"10.1016\/j.annonc.2022.07.1880","volume":"33","author":"J Wang","year":"2022","unstructured":"Wang J, Cheng Y, Wu Y, Cao F, Liu Q, Gao G. 1262TiP efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer. Ann Oncol. 2022;33:S1124\u2013S.","journal-title":"Ann Oncol"},{"issue":"12","key":"15142_CR45","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3779\/j.issn.1009-3419.2019.12.09","volume":"22","author":"G Pan","year":"2019","unstructured":"Pan G, Fan Y. [Progress of steroids effect on efficacy of immune checkpoint Inhibitors]. Zhongguo Fei Ai Za Zhi. 2019;22(12):786\u201393. https:\/\/doi.org\/10.3779\/j.issn.1009-3419.2019.12.09.","journal-title":"Zhongguo Fei Ai Za Zhi"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15142-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15142-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15142-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T10:13:19Z","timestamp":1764583999000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15142-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15142"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15142-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"22 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Sun Yat-sen University Cancer Center (ethics number: B2018-127-01). All participants provided written informed consent before enrolment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1840"}}